Atropen review

Atropen is a tropane alkaloid obtained from Atropa belladonna or deadly nightshade, Datura stramonium or jimsonweed, Mandragora officinarum or mandrake, and other plants of the family Solanaceae. This versatile, all-purpose medication is a secondary metabolite of the above plants and provides a wide variety of effects and uses. Classified as an anticholinergic medication, it serves as a competitive antagonist for the muscarinic acetylcholine receptor.

Because of Atropen's potential deadliness, the medication derives its name from one of the three Fates, Atropos, who according to Greek mythology chose how a person would die. The World Health Organization considers this a core medicine for the association's Essential Drugs List. This is a list of minimum medical requirements for a basic healthcare system.

Initial adult dosages range from around half a milligram to one milligram or five to ten milliliters of the 0.1 milligram/milliliter solution for antisialagogue and other antivagal effects, plus two to three milligrams or twenty to thirty milliliters of the 0.1 milligram/milliliter solution as an antidote for organophosporous muscarinic mushroom poisoning.

For patients without access to an IV, the endotracheal administration of Atropen should suffice because it doesn't need intravenous medication routes. The recommended adult dosage of Atropen for endotracheal administration is one to two milligrams diluted to a total not exceeding ten milliliters of normal saline or sterile water. Titration intervals of one or two hours are most suitable in cases that are not serious or critical.

Atropen Sulfate Injection (USP) should be administered with care and consideration given to all individuals over forty years of age. Acute glaucoma in susceptible patients may also occur during Atropen treatment. Conventional systemic dosages may lead to complete urinary retention in patients with prostatic hypertrophy, convert partial organic pyloric stenosis into complete obstruction, or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung illness. Inform your doctor of your medical history before starting treatment. This is of the utmost importance.

Even though the recurrent use of Atropen is crucial in patients suffering from coronary artery illness, the total dosage of the medicine should not exceed two to three (maximum 0.03 to 0.04 milligrams/kilograms) to prevent the harmful side effects of Atropen-caused tachycardia on myocardial oxygen demand.

As for patients suffering from bradyasystolic circulatory arrest, a single milligram dosage of Atropen should be taken intravenously and repeated every three to five minutes if symptoms persists. Three milligrams (0.04 milligrams/kilograms) given intravenously is a completely vagolytic dosage in most patients. Also, the administration of less than 0.05 milligrams can produce a paradoxical bradycardia because of the peripheral or central parasympathomimatic effects of low dosage Atropen in some adults.

As an antidote, Atropen's two to three milligram dosage should be repeated no less than every twenty to thirty minutes until symptoms are significantly reduced or signs of Atropen poisoning occur. Dosing information for children hasn't been well researched. Usage history of initial dosage is usually around 0.01 to 0.03 milligrams/kilograms of body weight.

Side effects directly related to Atropen include tachycardia, photophobia, blurred vision, and dryness of mouth. These symptoms commonly occur with chronic administration of therapeutic dosages. Anhidrosis, heat intolerance, and impaired temperature regulation may also occur to patients living in an arid environment. Elderly patients may also suffer urination difficulties and constipation. Occasional hypersensitivity, rashes, and exfoliation have also been reported. If you experience any of these symptoms, consult your doctor.

Side effects due to excessive dosage (Atropen poisoning) include ataxia, fatigue, tremor, restlessness, dizziness, thirst, hot and dry skin, difficulty swallowing, dilated pupils, and abnormality of heartbeat. Toxic dosages may lead to coma, delirium, hallucinations, restlessness and excitement, and marked abnormality of heartbeat. Severe intoxication while undergoing Atropen treatment can also lead to circulatory collapse and depression. Therefore patients will want to stay away from alcohol consumption while taking this medication. Consult your doctor immediately if you experience any of these symptoms.

Atropen has the following structural formula:

Chemical structure of atropen

• Molecular formula of atropen is C17H23NO3
• Chemical IUPAC Name is (8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl-propanoate
• Molecular weight is 289.369 g/mol
Atropen available : 5ml 1% bottles

Generic name: Atropine

Brand name(s): Atnaa, Atropair, Atropin, Atropina, Atropinol, Atropisol, Atrosulf, Equipin, Eyesules, Hyoscyamine, I-Tropine, Isopto atropine, Minims atropine, Ocu-Tropine, Tropine tropate, Troyl tropate

  Your Atropen review